Aimed at expanded its footprint in cell therapies, Charles River Laboratories (NYSE: CRL ) has agreed to acquire human-derived cellular products maker HemaCare ( OTCPK:HEMA ) for ~$380M in cash ($25.40 per share). More news on: Charles River Laboratories International, Inc., HemaCare Cor...
– Expands Charles River’s Scientific Capabilities in the High-Growth Cell Therapy Market – – Establishes a Comprehensive Cell Therapy Solution from Discovery through Commercialization – Charles River Laboratories International, Inc. (NYSE: CR...
Advancing cell and gene therapies with the highest quality GMP-compliant bone marrow starting material HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery,...
New distribution partnership allows high-quality human primary cells to reach the Chinese market HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and c...
HemaCare ( OTCPK:HEMA ): 1H net income of $4.5M Revenue of $19.5M (+49.2% Y/Y) Press Release More news on: HemaCare Corporation, Earnings news and commentary, Healthcare stocks news, ,
HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular process development, today announced operational highlights and financial results for the si...
Advancing discoveries by providing scientists with high-quality disease-state biospecimens to support preclinical and clinical research HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for bi...
HemaCare ( OTCPK:HEMA ): FY net income of $4.52M More news on: HemaCare Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced operational highlights and financial results for...
News, Short Squeeze, Breakout and More Instantly...
– Expands Charles River’s Scientific Capabilities in the High-Growth Cell Therapy Market – – Establishes a Comprehensive Cell Therapy Solution from Discovery through Commercialization – Charles River Laboratories International, Inc. (NYSE: CR...
Advancing cell and gene therapies with the highest quality GMP-compliant bone marrow starting material HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery,...
New distribution partnership allows high-quality human primary cells to reach the Chinese market HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and c...